Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Texas Roadhouse (TXRH) Reports Q2 Earnings: What Key Metrics Have to Say
Texas Roadhouse (TXRH) Reports Q2 Earnings: What Key Metrics Have to Say

Texas Roadhouse (TXRH) reported $1.51 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 12.7%. EPS of $1.86 for the same period compares to $1.79 a year

EOG Resources (EOG) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
EOG Resources (EOG) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended June 2025, EOG Resources (EOG) reported revenue of $5.48 billion, down 9.1% over the same period last year. EPS came in at $2.32, compared to $3.16 in the year-ago quarter.

The

Maplebear (CART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Maplebear (CART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2025, Maplebear (CART) reported revenue of $914 million, up 11.1% over the same period last year. EPS came in at $0.41, compared to $0.20 in the year-ago quarter.

The

Solventum (SOLV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Solventum (SOLV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Solventum (SOLV) reported $2.16 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 3.8%. EPS of $1.69 for the same period compares to $1.56 a year ago.

The

Mach Natural Resources LP (MNR) Surpasses Q2 Earnings and Revenue Estimates
Mach Natural Resources LP (MNR) Surpasses Q2 Earnings and Revenue Estimates

Mach Natural Resources LP (MNR) came out with quarterly earnings of $0.76 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.42 per share a year ago

Diodes (DIOD) Tops Q2 Earnings and Revenue Estimates
Diodes (DIOD) Tops Q2 Earnings and Revenue Estimates

Diodes (DIOD) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.33 per share a year ago. These figures are

GoDaddy (GDDY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
GoDaddy (GDDY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2025, GoDaddy (GDDY) reported revenue of $1.22 billion, up 8.3% over the same period last year. EPS came in at $1.41, compared to $1.10 in the year-ago quarter.

The

HP (HPQ) Gains As Market Dips: What You Should Know
HP (HPQ) Gains As Market Dips: What You Should Know

HP (HPQ) ended the recent trading session at $25.35, demonstrating a +1.36% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 0.08% for the

PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say
PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say

PTC Therapeutics (PTCT) reported $178.88 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 4.2%. EPS of -$0.83 for the same period compares to -$1.16 a

Guild Holdings Company (GHLD) Q2 Earnings Top Estimates
Guild Holdings Company (GHLD) Q2 Earnings Top Estimates

Guild Holdings Company (GHLD) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.49 per share a year ago

Microchip Tech (MCHP) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Microchip Tech (MCHP) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Microchip Technology (MCHP) reported $1.08 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 13.4%. EPS of $0.27 for the same period compares to $0.53 a

Here's What Key Metrics Tell Us About Expedia (EXPE) Q2 Earnings
Here's What Key Metrics Tell Us About Expedia (EXPE) Q2 Earnings

Expedia (EXPE) reported $3.79 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 6.4%. EPS of $4.24 for the same period compares to $3.51 a year ago.

The

scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

scPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.44 per share a year ago. These

Analog Devices (ADI) Ascends While Market Falls: Some Facts to Note
Analog Devices (ADI) Ascends While Market Falls: Some Facts to Note

Analog Devices (ADI) closed at $223.15 in the latest trading session, marking a +1.12% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.08%. On the other hand, the Dow

Why Monolithic Power's Earnings and Guidance Ignited a Rally
Why Monolithic Power's Earnings and Guidance Ignited a Rally

Following its July 31st earnings announcement, shares of Monolithic Power Systems (NASDAQ: MPWR) jumped more than 10% in a single session on unusually high trading volume. In the first few

Take-Two Interactive (TTWO) Beats Q1 Earnings and Revenue Estimates
Take-Two Interactive (TTWO) Beats Q1 Earnings and Revenue Estimates

Take-Two Interactive (TTWO) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.05 per share a year ago

ePlus (PLUS) Tops Q1 Earnings and Revenue Estimates
ePlus (PLUS) Tops Q1 Earnings and Revenue Estimates

ePlus (PLUS) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.13 per share a year ago. These figures are

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

Puma Biotech (PBYI) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.05 per share a year ago. These figures

OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago. These

Kratos (KTOS) Tops Q2 Earnings and Revenue Estimates
Kratos (KTOS) Tops Q2 Earnings and Revenue Estimates

Kratos (KTOS) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.14 per share a year ago. These figures are

Integral Ad Science (IAS) Q2 Earnings and Revenues Beat Estimates
Integral Ad Science (IAS) Q2 Earnings and Revenues Beat Estimates

Integral Ad Science (IAS) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.05 per share a year ago. These

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $0.94 per share a year

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.54 per share a year ago. These

Alta Equipment (ALTG) Reports Q2 Loss, Beats Revenue Estimates
Alta Equipment (ALTG) Reports Q2 Loss, Beats Revenue Estimates

Alta Equipment (ALTG) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.38 per share a year ago. These figures

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.59 per share a year ago. These